News
Dexamethasone appears promising for patients with severe illness.
Drugs in the Pipeline
Acalabrutinib, a Bruton tyrosine kinase (BTK) inhibitor, appears to reduce respiratory distress as well as the hyperinflammatory immune response associated with coronavirus disease 2019.
News
No significant difference seen in five-, 10-day course for severe COVID-19 without mechanical ventilation.
Drugs in the Pipeline
The FDA has granted Fast Track designation to intravenous choline chloride (Protara Therapeutics), an investigational phospholipid substrate replacement therapy for the treatment of intestinal failure-associated liver disease.
News
Treatment with remdesivir was associated with a shorter time to recovery in patients hospitalized with coronavirus disease 2019 (COVID-19), according to peer-reviewed data published in the New England Journal of Medicine.
Drugs in the Pipeline
The FDA has approved Octapharma’s Investigational New Drug Application allowing the Company to initiate a phase 3 trial of Octagam® (immune globulin intravenous [human]) in patients with COVID-19 with severe disease progression.
Drugs in the Pipeline
Following clearance of an Investigational New Drug Application by the Food and Drug Administration, ViralClear announced that a phase 2 study evaluating merimepodib oral solution for the treatment of coronavirus disease 2019 (COVID-19) will be initiated.
News
Treatment with inhaled nitric oxide has been shown to have both pulmonary and antiviral benefits.
ATS 2020
Inhaled nitric oxide 45 mcg/kg of ideal body weight per hour was effective for improving physical activity in patients at risk for pulmonary hypertension associated with fibrotic interstitial lung disease.
News
The Food and Drug Administration has cleared the initiation of a phase 3 trial evaluating INOpulse® inhaled nitric oxide (iNO) therapy (Bellerophon Therapeutics) in patients with coronavirus disease 2019 (COVID-19).